Agilent Technologies, Inc. (A) | The Buildout — AI Infrastructure
The Verdict
Agilent sells the instruments, software, services and consumables that laboratories use across the workflow — separating, measuring and identifying substances and samples. Its tools reach pharmaceutical research and manufacturing, clinical diagnostics and pathology, food, environmental and forensics testing, and chemicals and advanced materials. The AI build-out reaches it only indirectly: spectroscopy, vacuum and gas-chromatography tools go to semiconductor fabs and the chemical supply chains that feed them. Management frames AI more as an embedded tailwind and an internal productivity lever than as a standalone franchise, and the semiconductor slice is small.
| Market Cap | — |
| Revenue (TTM) | $7.4B |
| Revenue Growth | +8.6% |
| EBITDA Margin (TTM) | 25.9% |
| Net Debt | $2.2B |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Pricing has run at about 200 bps in each of Q1, Q2 and Q3 FY26, roughly double the original full-year target of more than 100 bps.
- Ex-refund operating margin expanded 210 bps year over year in Q3, and FY26 expansion guidance was raised to more than 100 bps ex-refund.
- Book-to-bill has been above 1 for 10 consecutive quarters, meaning instrument orders have met or grown faster than revenue.
- Train C, the CDMO capacity build-out, is on schedule for spring-2027 revenue, with 75% of FY27 available capacity spoken for with purchase orders.
- Reshoring orders arrived a quarter early — orders from 5 of the top 10 pharma companies in Q3 alone — and management sizes the opportunity at about $1B through 2030, expecting to win at least one-third.
What We’re Watching
- Whether the China swing from -9% to +9% holds: peers show China is not uniformly recovering, and Q4 is guided to high single digits.
- ATD/CDMO: Q4 is guided flattish against a more than 40% compare, leaving full-year growth implied below the prior mid-teens frame.
- Train C startup costs: management expects to hire staff and depreciate the facility before revenue arrives, with the margin drag to be mitigated through Ignite.
- Tariff refunds are one-time: the Q4 guide excludes future refunds, so the 27.2% ex-refund operating margin is the cleaner base.
The evidence points to a strengthening case: two sequential beat-and-raise quarters, pricing running at double the original plan, and orders converting faster than promised. It is not clean. The CDMO reset and the one-time tariff refund both mean the reported numbers flatter the underlying run rate, and China's inflection looks idiosyncratic next to weak peer China results. The open question is whether the reshoring and Train C commitments convert into FY27 revenue on the timeline management has framed.
Earnings Beat
Agilent reported Q3 FY2026 revenue of $1.88B, up 8.1% reported and 7.3% core, and above the high end of guidance by 140 bps. Gross margin was 55.5%. Reported operating margin was 28.3% including a $20M net tariff refund; ex-refund it was 27.2%, up 210 bps year over year. Book-to-bill came in above 1 for the 10th consecutive quarter.
| Metric | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $1.7B | +8.1% |
| Gross margin | 55.5% | 55.0% | 52.6% | +290bps |
| EBITDA | $510M | $466M | $432M | +18.1% |
| EPS | $1.28 | $1.19 | $1.18 | +8.5% |
| Book-to-bill | >1 | >1 | >1 | 10th straight quarter above 1 |
| Strategic pricing | ~200 bps | ~200 bps | well north of 100 bps | ~2x the prior year |
Make no mistake, our extraordinary Q3 results are no accident, nor are purely a function of improving end markets.— Padraig McDonnell, CEO, 2026-08-26
Management tone: Management's tone stepped up from the prior quarter. The Q3 language on Ignite escalated from 'structurally embedded' to 'compounding benefits… increasingly visible,' and the China commentary turned from defensive after Q2's -9% to bullish, with a detailed end-market walk-through in Q&A. Management was direct on mechanics such as lags and capacity, declined to frame FY27 quantitatively, and volunteered the ex-refund framing that separated a one-time tariff refund from the underlying margin.
Management Guidance
For FY26, management guides revenue of $7.49B–$7.51B and core growth of 5.8%–6.0%, with operating margin expansion above 100 bps ex-refund. Q4 is guided to revenue of $1.98B–$2.00B, including about $23M from Biocare and no future tariff refunds. Segment guidance is CAM high single digits and AMG mid-to-high single digits. Management declined to detail FY27 until the next call.
Trajectory
Revenue has moved from $1.80B in Q1 FY2026 to $1.84B in Q2 and $1.88B in Q3, with core growth of 7.3% in the latest quarter against 6.3% in Q2. EBITDA margin moved from 23.4% in Q1 to 25.4% in Q2 and 27.2% in Q3. Management credits pricing at about 200 bps, volume leverage, and Ignite-led procurement and factory productivity. Q4 core growth is guided to 5.2%–6.2%, below Q3, partly because ATD is expected to be flattish against a more than 40% compare.
The Model
The model projects FY+1 revenue of $8,066.5M with EBITDA of $2,416M (29.95%), and FY+2 revenue of $8,637.0M with EBITDA of $2,634M (30.5%). The near term rests on the raised FY26 guide plus the pricing and Ignite margin levers. FY+2 adds the Train C CDMO ramp from spring 2027 and pharma reshoring revenue that management says builds beginning in FY2027.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $6.9B | $8.1B | $8.6B |
| YoY Growth | — | +16.1% | +7.1% |
| EBITDA | $1.8B | $2.4B | $2.6B |
| EBITDA Margin | 25.4% | 29.9% | 30.5% |
Projections are the median of 4 independent model runs. The model’s revenue sits 3.6% above analyst consensus.
For FY26, management guides revenue of $7.49B–$7.51B and core growth of 5.8%–6.0%, with operating margin expansion above 100 bps ex-refund. Q4 is guided to revenue of $1.98B–$2.00B, including about $23M from Biocare and no future tariff refunds. Segment guidance is CAM high single digits and AMG mid-to-high single digits. Management declined to detail FY27 until the next call.
What Could Go Right — and Wrong
- Reshoring converts at or above the pace management framed — about $1B through 2030 with at least one-third won — and shows up in FY27 revenue.
- Train C ramps on schedule from spring 2027, converting the 75% of FY27 capacity already covered by purchase orders into revenue.
- Pricing holds near 200 bps into FY27, supporting the ex-refund margin trajectory.
- China momentum carries into FY27 without a stimulus tailwind, as management says it expects.
- ATD returns to mid-teens growth once Train C is online, making the FY26 reset a timing trough.
- The China swing reverses; peers show China is not uniformly recovering.
- Pricing reverts toward the original more-than-100 bps plan and ex-refund margin expansion stalls.
- ATD stays flattish or worsens into FY27 rather than ramping with Train C.
- Reshoring slips — management calls the revenue build 'not linear,' and no order value has been disclosed.
- One-time items persist or reverse; Q4 guidance excludes any future tariff refunds.
Looking Ahead
The next twelve months turn on converting commitments into reported revenue. Train C is due to generate revenue from spring 2027 and ramp over 6 to 8 quarters, and pharma reshoring revenue is expected to build in FY2027 and beyond. Management has said it will detail FY27 on the next call. China momentum, pricing durability and the ATD cadence are the swing factors, and the sector backdrop is supportive but uneven.
- Sept. 16, 2026Quarterly dividend declared — 25.5 cents per share, following the May 20, 2026 declaration.
- Q4 FY2026Q4 and FY26 results — Management has said it will detail FY27 on this call.
- Spring 2027Train C revenue start — CDMO capacity begins generating revenue, ramping over 6-8 quarters.
- FY2027Reshoring revenue builds — Orders from 5 of the top 10 pharma names are expected to convert.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $6.5B | $6.9B | $7.4B | +6.7% |
| Gross Margin | 54.3% | 52.5% | 53.7% | 188bps |
| EBITDA | $1.7B | $1.8B | $1.9B | +1.3% |
| EBITDA Margin | 26.8% | 25.4% | 25.9% | 137bps |
| Net Income | $1.3B | $1.3B | $1.4B | +1.1% |
| Free Cash Flow | $1.4B | $1.2B | $1.4B | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)53.7%
- EBITDA Margin (TTM)25.9%
- Net Margin (TTM)19.5%
- ROIC13.6%
- FCF Conversion75.2%
- SBC / Revenue1.8%
The Company
Agilent sells the instruments, software, services and consumables that laboratories use across the workflow — separating, identifying and measuring substances and samples. Its tools reach pharmaceutical research and manufacturing, clinical diagnostics and pathology, food, environmental and forensics testing, academia and government, and chemicals and advanced materials. Pharma is described as its largest end market, and the company's 10-K calls itself a global leader in life sciences, diagnostics and applied markets.
The company reports in three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets — and manufactures across the U.S., Europe and Asia. Accounting and tax processes are centralized in India and Malaysia. Agilent sells mostly direct, with distributors and e-commerce layered in, and it built the CrossLab services and consumables layer to monetize its installed base.
Business Segments
Competitive Landscape
Agilent competes across lab instruments, consumables and services. Its 10-K names Danaher, PerkinElmer, Shimadzu, Thermo Fisher and Waters across Applied Markets and CrossLab, and adds AB Sciex, Avecia, Bruker, Leica Biosystems, Roche Ventana and Twist Bioscience in Life Sciences and Diagnostics. The 10-K describes Agilent as the world's leading provider of gas chromatographs, both laboratory and portable models. Management also cites competitive wins in China, including with two leading CXOs and a PFAS testing lab, against a backdrop of about 15,000 instruments already installed at reshoring-designated customers.
- Thermo Fisher ScientificNamed in the 10-K as a competitor in LDG, ACG and AMG.
- DanaherNamed in the 10-K across its segments; parent of AB Sciex and Leica Biosystems, both named in LDG.
- ShimadzuNamed in the 10-K as a competitor in LDG, ACG and AMG.
- WatersNamed in the 10-K as a competitor in LDG, ACG and AMG.
- BrukerNamed in the 10-K as an LDG competitor.
Supply Chain
Agilent sits near the front of the laboratory workflow: it sells the instruments and then the services and consumables that follow them. Its filings say some custom-designed parts have no ready alternate source. No neighbor transcript names Agilent directly.
Related companies
See all Chip Making companies → · How this layer works: Chapter 1, The Chip →
More on A: Earnings recap